<bill session="116" type="h" number="2620" updated="2022-02-09T02:28:14Z">
  <state datetime="2019-05-09">REFERRED</state>
  <status>
    <introduced datetime="2019-05-09"/>
  </status>
  <introduced datetime="2019-05-09"/>
  <titles>
    <title type="display">Faster Treatments and Cures for Eye Diseases Act</title>
    <title type="official" as="introduced">To advance treatment and cures for blindness and other retinal conditions and to promote competitiveness in the United States through a pilot program to increase funding for translational research, and for other purposes.</title>
    <title type="short" as="introduced">Faster Treatments and Cures for Eye Diseases Act</title>
  </titles>
  <sponsor bioguide_id="B000490"/>
  <cosponsors>
    <cosponsor bioguide_id="B001257" joined="2019-05-09"/>
    <cosponsor bioguide_id="B001251" joined="2019-07-09"/>
    <cosponsor bioguide_id="C001068" joined="2019-05-09"/>
    <cosponsor bioguide_id="E000179" joined="2019-05-22"/>
    <cosponsor bioguide_id="F000466" joined="2019-05-09"/>
    <cosponsor bioguide_id="F000449" joined="2019-07-09"/>
    <cosponsor bioguide_id="H001068" joined="2019-08-09"/>
    <cosponsor bioguide_id="J000288" joined="2019-08-30"/>
    <cosponsor bioguide_id="L000593" joined="2020-02-11"/>
    <cosponsor bioguide_id="M001158" joined="2019-05-14"/>
    <cosponsor bioguide_id="M001159" joined="2019-05-09"/>
    <cosponsor bioguide_id="M001137" joined="2020-07-20"/>
    <cosponsor bioguide_id="O000171" joined="2019-05-09"/>
    <cosponsor bioguide_id="O000168" joined="2019-05-22"/>
    <cosponsor bioguide_id="R000515" joined="2019-08-30"/>
    <cosponsor bioguide_id="R000609" joined="2019-08-09"/>
    <cosponsor bioguide_id="S001190" joined="2019-05-09"/>
    <cosponsor bioguide_id="S001185" joined="2019-10-29"/>
    <cosponsor bioguide_id="S001200" joined="2019-07-10"/>
    <cosponsor bioguide_id="W000798" joined="2019-08-30"/>
    <cosponsor bioguide_id="W000797" joined="2019-06-12"/>
  </cosponsors>
  <actions>
    <action datetime="2019-05-09">
      <text>Introduced in House</text>
    </action>
    <action datetime="2019-05-09" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2019-05-10">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Congressional oversight"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug therapy"/>
    <term name="Executive agency funding and structure"/>
    <term name="Financial services and investments"/>
    <term name="Genetics"/>
    <term name="Government information and archives"/>
    <term name="Government lending and loan guarantees"/>
    <term name="Government studies and investigations"/>
    <term name="Health programs administration and funding"/>
    <term name="Health promotion and preventive care"/>
    <term name="Health technology, devices, supplies"/>
    <term name="Hearing, speech, and vision care"/>
    <term name="Interest, dividends, interest rates"/>
    <term name="Medical research"/>
    <term name="Public-private cooperation"/>
    <term name="Research administration and funding"/>
    <term name="Research and development"/>
    <term name="Securities"/>
    <term name="User charges and fees"/>
  </subjects>
  <amendments/>
  <summary date="2020-03-11T15:07:49Z" status="Introduced in House">Faster Treatments and Cures for Eye Diseases Act

This bill requires the Department of Health and Human Services to establish a pilot program that provides for a partial federal guarantee of specified bonds, the sale of which shall finance promising translational vision-impairment research with private investment. The Government Accountability Office must study this program and consider whether similar programs should be established for other areas of biomedical research.</summary>
</bill>
